On 3 April 2024 in Athens, the International Federationof Pharmaceutical Manufacturers and Associations (IFPMA) and the World Anti-Doping Agency (WADA) signed a joint letter of intent.
Read moreIFPMA has developed a Five-Phase Decision-Making Framework, grounded in the IFPMA Ethos or value system, to help companies make decisions that balance business objectives and ethical considerations to meet patient needs and the expectations of the medical community, regulators, and society.
Read moreWashington, D.C. and Geneva, 26 September 2023: This week, IFPMA joins hundreds of stakeholders from across economies in the Asia-Pacific at the APEC Business Ethics for SMEs Forum to recognize and applaud progress made by the initiative in the past decade to advance business ethics in the medical device and biopharmaceutical sectors in the region....
Read more